Site specific - Sarcoma

Sarcomas can arise within any site of the body and should have the ICD 10 and ICD-O-3 site code and the morphology code stated for each reportable Sarcoma.
The Cancer Waiting Times and COSD data sets have consistent inclusion criteria for sarcomas, although the COSD also includes C78.6 (“Secondary malignant neoplasm of retroperitoneum and peritoneum”).

For tumours coded under the C46 ICD-10 codes only the CORE data set needs to be completed.

ICD-10 codes

Note:

• please refer to Appendix A and B for site specific registerable ICD codes for sarcoma cancer patients

Retired data items

The following data items have been retired from v10:

• SA11010 – Sarcoma Tumour Subsite (Bone)
• SA11090 – Sarcoma Tumour Subsite (Soft Tissue)
• SA11025 – Multifocal or Synchronous Tumour Indicator
• CT6360 – Cytogenetics for Alveolar Rhabdomyosarcoma
• CT6460 – Cytogenetics for Ewings Sarcoma

This section is a child of 'Core-Diagnosis'.

May be up to one occurrence per CORE - Diagnosis (0..1)

Sarcoma Tumour Site (Bone)

Location of the bone sarcoma within the body as defined by OPCS4 code. This is (more specific than ICD10/ICDO3 sites).

Notes:

• use Cranium (Z639) for instances of Sarcoma of the Skull

• only use codes specified within this list; if new codes are required, please request these for v11 using the ‘Submit Change Request’ form

Sarcoma Tumour Site (Soft Tissue)

Location of the soft tissue sarcoma within the body as defined by OPCS4 code. This is (more specific than ICD10/ICDO3 sites).

Note:

• only use codes specified within this list; if new codes are required, please request these for v11 using the ‘Submit Change Request’ form

This is section provides a choice of 2 CTYA disease groups and associated data items.
Sarcoma - Diagnosis – Choice 0..1
Sarcoma - Diagnosis - Choice 1

End of Sarcoma - Diagnosis - Choice 1

Sarcoma - Diagnosis - Choice 2

End of Sarcoma - Diagnosis - Choice 2
End of Sarcoma - Diagnosis - Choice

IRS Post Surgical Group

IRS group defines the post-surgical disease status at diagnosis. This information should be available for the MDT discussion following treatment but will only apply to a small number of cases.

The following definitions are used:

• group 1 - primary complete resection
• group 2 - microscopic residual disease or primary complete resection with (completely resected) lymph node involvement
• group 3 - macroscopic residual disease
• group 4 - distant metastases

IRS Post Surgical Group Date

The date on which the IRS Post Surgical Group was recorded.

Rhabdomyosarcoma Site Prognosis Code

Grouping of anatomical sites which imply prognostic significance. This information should be available for the MDT discussion but will only apply to a small number of cases.

The following definitions are used:

• favourable sites: Orbit, genitourinary Non Bladder Prostate, Non-Parameningeal Head and Neck
• unfavourable sites: all other sites of disease

Tumour Volume at Diagnosis

Radiologically calculated estimate of tumour volume at diagnosis which has value in determining treatment.